A citation-based method for searching scientific literature

John R Webb, Katy Milne, David R Kroeger, Brad H Nelson. Gynecol Oncol 2016
Times Cited: 178







List of co-cited articles
714 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki, Taku Okazaki, Yoshimasa Tanaka, Ken Yamaguchi, Toshihiro Higuchi, Haruhiko Yagi, Kenji Takakura, Nagahiro Minato,[...]. Proc Natl Acad Sci U S A 2007
37

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
627
30

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Silvia Darb-Esfahani, Catarina Alisa Kunze, Hagen Kulbe, Jalid Sehouli, Stephan Wienert, Judith Lindner, Jan Budczies, Michael Bockmayr, Manfred Dietel, Carsten Denkert,[...]. Oncotarget 2016
156
28

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
22

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, Scott Rodig, Lauren L Ritterhouse, Joyce F Liu, Judy E Garber, Dipanjan Chowdhury, Catherine J Wu, Alan D D'Andrea,[...]. Oncotarget 2016
328
18

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
187
18

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, Jiyoung Ahn, Brian Bundy, Hiroyoshi Nishikawa, Feng Qian, Achim A Jungbluth, Denise Frosina, Sacha Gnjatic, Christine Ambrosone,[...]. Proc Natl Acad Sci U S A 2005
17


Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
151
16

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
16



Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Maureen L Drakes, Swati Mehrotra, Monica Aldulescu, Ronald K Potkul, Yueying Liu, Anne Grisoli, Cara Joyce, Timothy E O'Brien, M Sharon Stack, Patrick J Stiff. J Ovarian Res 2018
36
38

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Wei-Ting Hwang, Sarah F Adams, Emin Tahirovic, Ian S Hagemann, George Coukos. Gynecol Oncol 2012
366
14

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
S J L Mesnage, A Auguste, C Genestie, A Dunant, E Pain, F Drusch, S Gouy, P Morice, E Bentivegna, C Lhomme,[...]. Ann Oncol 2017
88
14

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
Ellen L Goode, Matthew S Block, Kimberly R Kalli, Robert A Vierkant, Wenqian Chen, Zachary C Fogarty, Aleksandra Gentry-Maharaj, Aleksandra Tołoczko, Alexander Hein, Aliecia L Bouligny,[...]. JAMA Oncol 2017
132
13

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
913
12

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, Janice M Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei. Gynecol Oncol 2019
89
13

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
11

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
11

Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
Jayanta Chatterjee, Wei Dai, Nor Haslinda Abd Aziz, Pei Yun Teo, John Wahba, David L Phelps, Christian J Maine, Lynsey M Whilding, Roberto Dina, Giorgia Trevisan,[...]. Clin Cancer Res 2017
36
30

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
10

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
10

The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk. Gynecol Oncol Res Pract 2016
86
11

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
K Abiko, N Matsumura, J Hamanishi, N Horikawa, R Murakami, K Yamaguchi, Y Yoshioka, T Baba, I Konishi, M Mandai. Br J Cancer 2015
361
10


Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
10

Immune checkpoint inhibition in ovarian cancer.
Junzo Hamanishi, Masaki Mandai, Ikuo Konishi. Int Immunol 2016
82
10

Classifying Cancers Based on T-cell Infiltration and PD-L1.
Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, Mark J Smyth. Cancer Res 2015
783
9

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
Janis M Taube, Robert A Anders, Geoffrey D Young, Haiying Xu, Rajni Sharma, Tracee L McMiller, Shuming Chen, Alison P Klein, Drew M Pardoll, Suzanne L Topalian,[...]. Sci Transl Med 2012
9

Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Anne M Mills, Lauren C Peres, Alice Meiss, Kari L Ring, Susan C Modesitt, Sarah E Abbott, Anthony J Alberg, Elisa V Bandera, Jill Barnholtz-Sloan, Melissa L Bondy,[...]. Int J Gynecol Pathol 2019
21
42

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Jun Zhu, Hao Wen, Rui Bi, Yong Wu, Xiaohua Wu. J Gynecol Oncol 2017
26
34

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.
Allen W Zhang, Andrew McPherson, Katy Milne, David R Kroeger, Phineas T Hamilton, Alex Miranda, Tyler Funnell, Nicole Little, Camila P E de Souza, Sonya Laan,[...]. Cell 2018
138
9


PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.
Laura Martin de la Fuente, Sofia Westbom-Fremer, Nicolai Skovbjerg Arildsen, Linda Hartman, Susanne Malander, Päivi Kannisto, Anna Måsbäck, Ingrid Hedenfalk. Virchows Arch 2020
21
42

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Jérôme Galon, Anne Costes, Fatima Sanchez-Cabo, Amos Kirilovsky, Bernhard Mlecnik, Christine Lagorce-Pagès, Marie Tosolini, Matthieu Camus, Anne Berger, Philippe Wind,[...]. Science 2006
8


Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
Roel G W Verhaak, Pablo Tamayo, Ji-Yeon Yang, Diana Hubbard, Hailei Zhang, Chad J Creighton, Sian Fereday, Michael Lawrence, Scott L Carter, Craig H Mermel,[...]. J Clin Invest 2013
361
8

Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Charlotte S Lo, Sanaz Sanii, David R Kroeger, Katy Milne, Aline Talhouk, Derek S Chiu, Kurosh Rahimi, Patricia A Shaw, Blaise A Clarke, Brad H Nelson. Clin Cancer Res 2017
81
9

The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.
Galaxia M Rodriguez, Kristianne J C Galpin, Curtis W McCloskey, Barbara C Vanderhyden. Cancers (Basel) 2018
54
14

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero,[...]. JAMA Oncol 2019
149
8

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Janis M Taube, Alison Klein, Julie R Brahmer, Haiying Xu, Xiaoyu Pan, Jung H Kim, Lieping Chen, Drew M Pardoll, Suzanne L Topalian, Robert A Anders. Clin Cancer Res 2014
7

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
767
7

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
7

Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll. Cancer Cell 2015
7

Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Mengjiao Li, Haoran Li, Fei Liu, Rui Bi, Xiaoyu Tu, Lihua Chen, Shuang Ye, Xi Cheng. J Ovarian Res 2017
29
24

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.
Verena Wieser, Inge Gaugg, Martina Fleischer, Giridhar Shivalingaiah, Soeren Wenzel, Susanne Sprung, Sigurd F Lax, Alain G Zeimet, Heidelinde Fiegl, Christian Marth. Oncotarget 2018
47
14

Tumor infiltrating lymphocytes in ovarian cancer.
Phillip P Santoiemma, Daniel J Powell. Cancer Biol Ther 2015
144
7

The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
Jun Li, Jieyu Wang, Ruifang Chen, Yang Bai, Xin Lu. Oncotarget 2017
90
7

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Brooke E Howitt, Kyle C Strickland, Lynette M Sholl, Scott Rodig, Lauren L Ritterhouse, Dipanjan Chowdhury, Alan D D'Andrea, Ursula A Matulonis, Panagiotis A Konstantinopoulos. Oncoimmunology 2017
57
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.